Glomerular Filtration Rate, Cardiorenal End Points, and All-Cause Mortality in Type 2 Diabetic Patients

  1. Wing Yee So, MBCHB, FRCP1,
  2. Alice P.S. Kong, MBCHB, FRCP12,
  3. Ronald C.W. Ma, MBBCHIR, MA, MRCP1,
  4. Risa Ozaki, MBCHB, MRCP1,
  5. Cheuk Chun Szeto, MBCHB, FRCP1,
  6. Norman N. Chan3,
  7. Vanessa Ng, MBCHB, MRCP1,
  8. Chung Shun Ho, PHD4,
  9. Christopher W.K. Lam, PHD4,
  10. Chun Chung Chow, MBCHB, FRCP1,
  11. Clive S. Cockram, MD, FRCP1,
  12. Juliana C.N. Chan, MD, FRCP1 and
  13. Peter C.Y. Tong, MBCHB, FRCP1
  1. 1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shantin, N.T., Hong Kong
  2. 2Li Ka Shing Institute of Health Sciences, Hong Kong, Hong Kong
  3. 3Qualigenics Diabetes Centre, Hong Kong, Hong Kong
  4. 4Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shantin, N.T., Hong Kong
  1. Address correspondence and reprint requests to Dr. Juliana C.N. Chan, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR. E-mail: jchan{at}


OBJECTIVE—Chronic kidney disease (CKD) predicts cardiovascular disease (CVD) in the general population. We investigated the effects of stages of renal function using the estimated glomerular filtration rate (eGFR) on all-cause mortality and cardiovascular end points in a prospective cohort of Chinese type 2 diabetic patients.

RESEARCH DESIGN AND METHODS—Between 1995 and 2000, 4,421 patients without macrovascular disease or end-stage renal disease were recruited. Renal function was assessed by eGFR, as calculated by the abbreviated Modification of Diet in Renal Disease Study Group formula. Clinical end points included all-cause mortality, cardiovascular end point (cardiovascular death, new admissions due to angina, myocardial infarction, stroke, revascularization, or heart failure), and renal end point (reduction in eGFR by >50%, progression of eGFR to stage 5, or dialysis or renal death).

RESULTS—After a median follow-up period of 39.4 months (interquartile range 20.3–55), all-cause mortality rate increased from 1.2% (95% CI 0.8–1.7) to 18.3% (9.1–27.5) (P for trend <0.001) as renal function deteriorated from stage 1 (eGFR ≥90 ml/min per 1.73 m2) to stage 4 (15–29 ml/min per 1.73 m2). The respective rate of new cardiovascular end points also increased from 2.6% (2.0–3.3) to 25.3% (15.0–35.7) (P for trend <0.001). After adjustment for covariates (age, sex, albuminuria, use of renin-angiotensin-aldosterone system [RAAS] inhibitors, lipids, blood pressure, and glycemic control), hazard ratios across different stages of eGFR (≥90, 60–89, 30–59, and 15–29 ml/min per 1.73 m2) for all-cause mortality were 1.00, 1.27, 2.34, and 9.82 (P for trend <0.001), for cardiovascular end points were 1.00, 1.04, 1.05, and 3.23 (P for trend <0.001), and for renal end points were 1.00, 1.36, 3.34, and 27.3 (P for trend <0.001), respectively.

CONCLUSIONS—Chinese type 2 diabetic patients with reduced eGFR were at high risk of developing cardiovascular end points and all-cause mortality, independent of albuminuria and metabolic control.


  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 8, 2006.
    • Received January 31, 2006.
| Table of Contents